Related Experiment Videos
Sumatriptan does not stimulate PRL and GH secretion in acromegaly
C M Cuttica1, P Sessarego, S Valenti
1University of Genova, DISEM, Cattedra di Endocrinologia.
Minerva Endocrinologica
|June 1, 1995
Summary
Sumatriptan, a 5-HT1D receptor agonist, did not affect prolactin secretion in acromegaly patients or controls. It increased growth hormone in controls but not in acromegalics.
Area of Science:
- Endocrinology
- Neuropharmacology
Background:
- Serotoninergic receptors play a role in regulating prolactin (PRL) and growth hormone (GH) secretion.
- Sumatriptan is a selective 5-HT1D receptor agonist.
Purpose of the Study:
- To investigate the effects of sumatriptan on PRL and GH secretion in patients with active acromegaly.
- To compare these effects with those in age-matched normal subjects.
Main Methods:
- A single-blind, randomized study involving 8 acromegalic patients and 10 normal subjects.
- Administration of sumatriptan (6 mg subcutaneously) or placebo.
- Monitoring of PRL and GH levels via blood sampling before and for 2 hours after administration.
Main Results:
- Sumatriptan did not significantly alter PRL secretion in either group.
- A significant increase in GH levels was observed in normal subjects but not in acromegalic patients after sumatriptan administration.
- A negative age-related trend in GH response to sumatriptan was noted in normal subjects.
Conclusions:
- The 5-HT1D receptor is not implicated in the regulation of PRL and GH secretion in middle-aged acromegalic patients.
- The findings suggest differential effects of 5-HT1D receptor agonism on GH secretion between acromegalic and normal individuals.